Company Overview - iRhythm Holdings, Inc. is a digital healthcare company specializing in innovative cardiac monitoring solutions, with its core offering being the Zio platform that utilizes wearable biosensors and advanced analytics for improved arrhythmia detection and diagnosis [5] - The company generates revenue primarily through sales of its Zio service, which combines device sales with subscription-based monitoring and diagnostic services for healthcare providers [8] - As of the latest financial data, iRhythm reported a total revenue of $747.1 million and a net income of -$44.6 million [3] Recent Developments - RTW Investments disclosed a new position in iRhythm Holdings, acquiring 1,181,990 shares valued at approximately $210 million during the fourth quarter of 2025 [1] - This new position represents 2.1% of RTW's total 13F-reported portfolio, indicating a significant commitment from the fund [6][7] - As of March 19, 2026, shares of iRhythm Holdings were priced at $117.78, reflecting a one-year price change of 14.2%, which underperformed the S&P 500 by 3.5 percentage points [7] Market Position - iRhythm Holdings operates at the intersection of medical devices and digital health, with its flagship Zio patch being a discreet, wearable cardiac monitor that has established a strong niche in ambulatory ECG monitoring [10] - The Zio system collects continuous data over days or weeks, providing physicians with a comprehensive view of a patient's heart rhythm, which enhances its value compared to traditional Holter monitors [10] - The combination of hardware, software, and services allows iRhythm to maintain a recurring revenue model that is potentially more stable than simple device sales [10]

Core Insights - iRhythm Holdings, Inc. (NASDAQ:IRTC) is recognized as one of the fastest growing mid-cap stocks, with significant revenue growth and positive profitability metrics reported for Q4 2025 [1][2]. Financial Performance - For Q4 2025, iRhythm reported revenue of $208.9 million, marking a 27.1% increase year-over-year. The company achieved a net income of $5.6 million and a gross margin of 70.9%, indicating its first quarter of positive GAAP profitability [3][8]. - The total revenue for the full year 2025 reached $747.1 million, reflecting a 26.2% annual growth. The gross margin slightly decreased to 70.6%, while the net loss improved to $44.6 million compared to the previous year. Notably, the company generated positive free cash flow of $34.5 million for the first time in a full year [4]. Business Model and Strategy - iRhythm is a digital healthcare company specializing in cardiac monitoring solutions, utilizing its flagship Zio platform, which incorporates wearable biosensors and AI-driven analytics to enhance the diagnosis of heart conditions [5]. - The company attributes its success to innovative care channels, expansion into international markets, and sustained demand within its core U.S. business, with a focus on growth, margin expansion, and prudent investment as it approaches 2026 [4].

iRhythm Technologies Conference Summary Company Overview - **Company**: iRhythm Technologies (NasdaqGS: IRTC) - **Industry**: Digital healthcare focused on cardiac monitoring - **Event**: Jefferies London Healthcare Conference, November 20, 2025 Key Points Product and Technology - iRhythm's Zio platform combines hardware, software, and services for cardiac monitoring [2][4] - The Zio Monitor is a patented wearable biosensor that can be worn for up to 14 days, capturing an average of 1.5 million heartbeats [3][4] - The company has developed a second-generation FDA-cleared deep-learning algorithm, with a third generation in development [4] Financial Performance - Reported revenue for Q3 was $192.9 million, representing a year-over-year growth of 30.7% [5][23] - The company serves over 2 million patients annually and has a 30% share in its core market [5] - Guidance for full-year revenue is between $735 million and $740 million, indicating a 24-25% year-over-year growth [24] Market Opportunity - iRhythm identifies a total addressable market (TAM) of 27 million patients who are candidates for Zio monitoring [5][12] - The U.S. market for long-term continuous monitoring is approximately 3 million tests, where iRhythm holds over 70% market share [9] - Internationally, the company is targeting 5 million tests in prioritized countries, including the U.K., Japan, and several Western European nations [10][11] Clinical Evidence and Research - iRhythm has published 125 scientific manuscripts demonstrating the clinical and economic superiority of the Zio platform [6] - The company has a database of 2.5 billion hours of curated ECG data, enhancing the effectiveness of its AI tools [6] Strategic Initiatives - The company is pursuing a "Land and Expand" strategy to penetrate primary care markets [14][15] - EHR integration is a key focus, with over 50% of volume running through EHR systems, enhancing workflow efficiency [20][21] - iRhythm is developing a multivitals platform to gather additional patient data, targeting adjacent markets such as sleep monitoring [22][23] Financial Health and Future Outlook - Gross margin expanded to 71.1% in the most recent quarter, with a long-term target of 72-73% by 2027 [24] - Adjusted EBITDA margin was 11.2%, with a target of 15% by 2027 [24] - The company expects to be free cash flow positive for the first time in 2025, marking a significant milestone [25] Conclusion - iRhythm Technologies is well-positioned for sustainable growth, with significant market expansion opportunities and a strong focus on innovation and operational efficiency [26]